PuSH - Publikationsserver des Helmholtz Zentrums München

Reguraman, N.* ; Hassani, A.* ; Philip, P.S.* ; Pich, D. ; Hammerschmidt, W. ; Khan, G.*

Assessing the efficacy of VLP-based Vaccine against Epstein-Barr Virus using a rabbit model.

Vaccines 11:14 (2023)
Verlagsversion DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
Epstein-Barr virus (EBV) is etiologically associated with a number of malignant and non-malignant conditions. Thus, a prophylactic vaccine against this virus could help to reduce the burden of many EBV-associated diseases. Previously, we reported that an EBV virus-like particle (VLP) vaccine was highly immunogenic and produced a strong humoral response in mice. However, since EBV does not infect mice, the efficacy of the VLP in preventing EBV infection could not be addressed. Here we examined, for the first time, the efficacy of the EBV-VLP vaccine using a novel rabbit model of EBV infection. Animals vaccinated with two doses of VLP elicited higher antibody responses to total EBV antigens compared to animals receiving one dose. Vaccinated animals also elicited both IgM and IgG to EBV-specific antigens, VCA and EBNA1. Analysis of peripheral blood and spleen for EBV copy number indicated that the viral load in both of these compartments was lower in animals receiving a 2-dose vaccine. However, the VLP vaccine was ineffective in preventing EBV infection. With several other EBV vaccine candidates currently at various stages of development and testing, we believe that the rabbit model of EBV infection could be a great platform for evaluating potential candidates.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
7.800
0.000
1
1
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Ebv ; Vlp ; Booster Dose ; Immune Response ; Rabbits ; Vaccine; Phase-i Trial; Packaging Cell-line; Ebv Infection; Recombinant Vaccinia; Animal-model; B-cells; Particles; Gp350; Glycoprotein; Persistence
Sprache englisch
Veröffentlichungsjahr 2023
HGF-Berichtsjahr 2023
e-ISSN 2076-393X
Zeitschrift Vaccines
Quellenangaben Band: 11, Heft: 3, Seiten: , Artikelnummer: 14 Supplement: ,
Verlag MDPI
Verlagsort Basel
Begutachtungsstatus Peer reviewed
POF Topic(s) 30203 - Molecular Targets and Therapies
Forschungsfeld(er) Immune Response and Infection
PSP-Element(e) G-501500-001
Scopus ID 85151921776
PubMed ID 36992124
Erfassungsdatum 2023-10-06